Piscataway, NJ2 Active Studies

Multiple Sclerosis Clinical Trials in Piscataway, NJ

Find 2 actively recruiting multiple sclerosis clinical trials in Piscataway, NJ. Connect with local research sites and explore new treatment options.

2
Active Trials
2
Sponsors
360
Enrolling

Recruiting Multiple Sclerosis Studies in Piscataway

About Multiple Sclerosis Clinical Trials in Piscataway

Multiple sclerosis (MS) is an autoimmune disease where the immune system attacks the protective covering of nerve fibers, causing communication problems between the brain and body. Symptoms vary widely and can include vision problems, fatigue, and mobility issues. Disease-modifying therapies have significantly improved outcomes.

There are currently 2 multiple sclerosis clinical trials recruiting participants in Piscataway, NJ. These studies are seeking a combined 360 participants. Research is being sponsored by Janssen Research & Development, LLC, Rutgers, The State University of New Jersey. Clinical trial participation is free and participants receive study-related medical care at no cost.

Multiple Sclerosis Clinical Trials in Piscataway — FAQ

Are there multiple sclerosis clinical trials in Piscataway?

Yes, there are 2 multiple sclerosis clinical trials currently recruiting in Piscataway, NJ. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Piscataway?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Piscataway research site will contact you about next steps.

Are clinical trials in Piscataway free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Piscataway studies also compensate for your time and travel.

What multiple sclerosis treatments are being tested?

The 2 active trials in Piscataway are testing new therapies including novel drugs, biologics, and treatment approaches for multiple sclerosis.

Data updated July 19, 2026 from ClinicalTrials.gov